Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Gumi-ro 300, Seongnam-si, Gyunggi-do, Republic of Korea.
Anticancer Res. 2012 Aug;32(8):3467-71.
The use of cell-free DNA (cfDNA) as a non-invasive biomarker has been evaluated in many types of cancer. This study investigated the prognostic significance of cfDNA level for ovarian cancer.
Preoperative sera of 36 patients with ovarian cancer and of 16 with benign tumors were analyzed using commercially available copy number assay kits to measure the cfDNA level of genes including beta-2-microglobulin (B2M), member RAS oncogene family (RAB25), claudin 4 (CLDN4) and ATP-binding cassette subfamily F member 2 (ABCF2). Cox regression analysis was used to calculate hazard ratios (HR) and 95% confidence intervals (CI).
cfDNA level of these genes had no association with other prognostic factors of ovarian cancer. In particular, in patients with advanced stage disease, a low RAB25 level was an independent prognostic factor for disease-free survival (HR=18.2, 95% CI=2.0-170.0) and overall survival (HR=33.6, 95% CI=1.8-634.8).
Our findings suggest that the preoperative serum cfDNA level of RAB25 could be a useful biomarker predicting survival outcomes in patients with advanced ovarian cancer.
无细胞 DNA（cfDNA）作为一种非侵入性生物标志物，已在多种类型的癌症中得到评估。本研究探讨了 cfDNA 水平对卵巢癌的预后意义。
使用商业上可用的拷贝数测定试剂盒分析 36 例卵巢癌患者和 16 例良性肿瘤患者的术前血清，以测量包括β-2-微球蛋白（B2M）、RAS 癌基因家族成员（RAB25）、紧密连接蛋白 4（CLDN4）和 ATP 结合盒亚家族 F 成员 2（ABCF2）在内的基因的 cfDNA 水平。Cox 回归分析用于计算风险比（HR）和 95%置信区间（CI）。
这些基因的 cfDNA 水平与卵巢癌的其他预后因素无关。特别是在晚期疾病患者中，RAB25 水平低是无病生存（HR=18.2，95%CI=2.0-170.0）和总生存（HR=33.6，95%CI=1.8-634.8）的独立预后因素。
我们的研究结果表明，术前血清 RAB25 的 cfDNA 水平可能是预测晚期卵巢癌患者生存结局的有用生物标志物。
